Sanofi Goes All The Way In mRNA With Translate Bio Buy
French Giant Paying $3.2bn
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
You may also be interested in...
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
Sanofi’s $1.9bn cash purchase of Kadmon surprised many analysts, coming as a bolt-on for the French pharma’s general medicines transplant portfolio rather than its specialty care pipeline, but the overall view was that it made sense.